241 related articles for article (PubMed ID: 25674762)
21. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
22. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
23. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
24. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
25. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T
Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980
[TBL] [Abstract][Full Text] [Related]
27. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
28. Metadherin Expression is Associated with Extrathyroidal Extension in Papillary Thyroid Cancer Patients.
Moore RF; Sholl AB; Kidd L; Al-Qurayshi Z; Tsumagari K; Emejulu OM; Kholmatov R; Friedlander P; Abd Elmageed ZY; Kandil E
Ann Surg Oncol; 2016 Sep; 23(9):2883-8. PubMed ID: 27146414
[TBL] [Abstract][Full Text] [Related]
29. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
30.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
31. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
32. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
33. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.
Pelttari H; Schalin-Jäntti C; Arola J; Löyttyniemi E; Knuutila S; Välimäki MJ
APMIS; 2012 May; 120(5):380-6. PubMed ID: 22515292
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
[TBL] [Abstract][Full Text] [Related]
36. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
37. [BRAF initiating mutations in the papillary thyroid carcinoma].
Rusinek D; Gubała E
Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
[TBL] [Abstract][Full Text] [Related]
38. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
[TBL] [Abstract][Full Text] [Related]
39. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
40. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]